The fundamentals are still what determine your long-term health
Evidence-based approaches to weight loss address the fundamental behaviours and patterns that influence weight, rather than promising magic solutions
This analysis uses 2023 Medicare claims for traditional Medicare, Medicare Advantage encounter data, and Part D prescription drug event data to estimate the total number of Medicare beneficiaries with obesity or overweight, the number of Part D enrollees who met the Bridge eligibility criteria in 2023, and those who met the Bridge clinical criteria but who also had diagnoses recorded in claims or encounter data that would qualify for Part D coverage of GLP-1s (type 2 diabetes, OSA, or MASH) or who had a GLP-1 Part D-covered prescription during the year, either of which would make them ineligible for Bridge (see Methods)
When Novo Nordisk faced production issues, choosing Eli Lilly's Mounjaro and Zepbound over Novo Nordisk's Wagovy became easier
Retatrutide funciona de manera similar, pero adems de GLP-1, tambin acta sobre otras dos hormonas
